Question 1

What is enGene's focus?

Accepted Answer

enGene is developing locally administered, non-viral gene therapies for rare genetic diseases, with the goal of mainstreaming gene therapy beyond just rare conditions.

Question 2

What is the company's lead product candidate?

Accepted Answer

enGene's lead product candidate is detalimogene voraplasmid, a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC).

Question 3

What is the advantage of enGene's gene delivery platform?

Accepted Answer

enGene's novel gene delivery platform, the DDX® platform, offers localized delivery of multiple gene cargos directly to mucosal tissues and other organs, potentially overcoming the limitations of viral-based gene therapies.

Question 4

What is the potential impact of enGene's technology?

Accepted Answer

By advancing gene therapy beyond rare genetic diseases, enGene's technology has the potential to bring the benefits of genetic medicine to a wider range of patients and clinical settings.

Question 5

Where can I find more information about enGene?

Accepted Answer

Detailed information about enGene's science, pipeline, and corporate updates can be found on the company's website at engene.com, including presentations, press releases, and SEC filings.

enGene

Company Overview

Company Name

Address

Website

Phone

About enGene

More Companies in British Columbia

Frequently Asked Questions about enGene

What is enGene's focus?

What is the company's lead product candidate?

What is the advantage of enGene's gene delivery platform?

What is the potential impact of enGene's technology?

Where can I find more information about enGene?

Technologies Used

Social Profiles

Key Decision Makers